Author name: manisahilvelive

Stratos BioCapital is proud to announce the launch of ImmunaGenix, a next-generation biotech company focused on developing precision immunotherapies for autoimmune diseases and cancer. Backed by Stratos, ImmunoGenix is pioneering novel approaches to immune modulation, leveraging advanced antibody engineering and cellular therapy platforms. A New Era in ImmunotherapyImmunoGenix is dedicated to tackling some of the […]

The J.P. Morgan Healthcare Conference 2025, held in San Francisco from January 13-16, once again set the stage for the year ahead in biotechnology and healthcare investment. As one of the industry’s most anticipated annual events, the conference brought together global leaders, innovators, and investors to discuss the latest developments, opportunities, and challenges shaping the

As we step into 2025, the biotech industry is at a pivotal moment, driven by AI-powered drug discovery, ground-breaking advances in obesity and metabolic treatments, and an unprecedented surge in cell and gene therapies. At Stratos BioCapital, we continue to focus on high-impact investments that align with these transformative trends. 1. The AI-Driven Revolution in

Mentara Bio, a portfolio company of Stratos BioCapital, is at the forefront of developing innovative treatments for neurological disorders. By integrating cutting-edge brain science with advanced technologies, Mentara Bio aims to address unmet medical needs in conditions such as epilepsy and neurodegenerative diseases. Innovative Research and Development Mentara Bio’s mission is to harness advanced neuroscience